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Numerous cross-sectional and some longitudinal
studies have described the health-related quality of
life and psychosocial sequelae of survivors after hema-
topoietic cell transplantation (HCT). The majority of
HCT survivors seem to do well with regard to their
overall physical, psychologic, social, and spiritual
well-being. However, psychosocial recovery can take
longer than physical recovery, and for many, signifi-
cant residual difficulties remain, including fatigue,
distress, sexual problems, and cognitive difficulties.
Family caregivers also can experience long-lasting ad-
verse effects from the transplant and caregiving experi-
ences. This brief review will focus primarily on studies
of long-term survivors and caregivers (at least 1 year
post-HCT) conducted in the last decade (see Mosher
et al. [1] for a detailed review of these issues). Although
there are no data on the effectiveness of psychosocial
interventions in long-term HCT survivors, interven-
tions effective with survivors in the peritransplant pe-
riod and with non-HCT cancer survivors will be
noted, along with suggestions for the future.FATIGUE
One of the most frequently reported symptoms of
HCT survivors is fatigue. A subjective sense of physi-
cal, emotional, and/or cognitive exhaustion that is dis-
proportional to recent activity and interferes with
functioning, fatigue does not appear to resolve with
time [2]. Approximately one-third of autologous and
allogeneic 2-year survivors reported being bothered
‘‘a lot’’ or ‘‘extremely’’ by fatigue [2]. Fatigue levels
have exceeded population norms in long-term survi-
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study found that autologous HCT survivors reported
more fatigue than allogeneic HCT recipients after 3
years [3]. Although the specific cause of persistent
fatigue is unknown, a number of physiologic, bio-
chemical, and psychologic mechanisms have been pos-
tulated. Several randomized trials provide evidence of
the effectiveness of exercise interventions to reduce fa-
tigue andmedical complications, and improve physical
performance and quality of life, with no reported
negative effects (see review [5]). Other studies have
found energy improvement with administration of
erythropoietin and cognitive-behavior therapy that in-
cluded relaxation training. However, all these studies
have been conducted in the peritransplant setting,
and need to be replicated with long-term survivors.
Clinical practice guidelines for fatigue are available
from the National Comprehensive Cancer Network
(NCCN; www.NCCN.org), which recommend use
of a single-item screening question and provide a treat-
ment decision tree.DISTRESS, DEPRESSION, ANXIETY, AND
POSTTRAUMATIC STRESS
DISORDER (PTSD)
Distress, suggested by some as ‘‘the sixth vital
sign,’’ is ubiquitous among HCT survivors. Distress
includes the continuum of subclinical feelings of vul-
nerability, sadness, and fear to clinically significant
depression, anxiety, and PTSD. Almost all survivors
report fear of recurrence, regardless of the number of
years since transplant. Financial concerns also are
common in both autologous and allogeneic HCT sur-
vivors [2] and 10-year survivors were more likely than
matched controls to have experienced denial of life and
health insurance [6]. Other significant concerns of sur-
vivors are noted in Table 1.
Clinically significant depressive symptoms have
been reported in 9%-35% of long-term HCT survi-
vors [2,4,7], levels higher than in matched controls
[4]. Others have not found elevations of depression
in long-term survivors [3,6], but have found elevations
in anxiety in 18% of 10-year survivors, compared to
10% in matched controls [6]. PTSD also has been29
Table 1. Sources of Distress for HCT Survivors
Physical Problems/Medical Concerns Psychologic Problems
Social and Community
Reintegration Problems Spiritual/Existential Concerns
 Fatigue/stamina  Fear of recurrence  Return to former roles
(parenting, spousal,
work, community)
 Spiritual crisis (loss of faith,
feeling of being punished
or forsaken)
 Continued health problems
(eg, GVHD, joint, skin,
lung problems)
 Uncertainty of future
for self and family
 Resumption of social
relations
 Loss of hope
 Late effects  Disrupted life plans
related to education,
job/career, retirement
 Relationship/marital problems  Loss of life purpose or
meaning in life
 Cognitive difficulties  Guilt (survivor guilt, family
burden)
 Employment and insurance
discrimination
 Disappointment or disconnection
with former religious/spiritual
community
 Sleep difficulties  Diminished self-worth
(‘‘damaged’’ by treatment,
dependent on others)
 Financial insecurity
(treatment-related expenses,
debt, reduced earning ability)
 Sexual dysfunction and/
or infertility
 Wondering if they will
‘‘return to normal’’
 Appearance changes
 Appetite problems
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-versus-host disease.
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vors of HCT [1].
Better pretransplant psychologic functioning, bet-
ter posttransplant physical and sexual functioning, and
less fatigue are all associated with less distress. Having
chronic graft-versus-host disease (cGVHD) and low
social support has been associated with depression in
survivors. Associations between distress or depression
and demographic and medical variables have been
mixed. Distress has been associated with medication
nonadherence [7], and depression was found to be an
independent predictor of death (threefold greater
risk) in the first 12 months after HCT, adjusting for
other prognostic factors [8]. These findings under-
score the need for regular assessment of distress
(shown to be feasible [7]), followed by appropriate
treatment. Commonly used self-report measures of
depression or anxiety may not fully capture the fears
and concerns of HCT survivors; thus, specific mea-
sures of cancer-related distress should be considered.
Clinical practice guidelines from the NCCN are avail-
able for distress, as well, (www.NCCN.org), which
recommend use of the Distress Thermometer, a 1-
item screening measure, validated in HCT patients.
Although there are few studies of psychologic inter-
ventions with HCT survivors, there exists a large,
applicable, evidence-base for effective psychosocial
interventions with cancer patients (see meta-analysis
of randomized trials [9]).
SEXUAL PROBLEMS
Sexual problems are frequently reported by survi-
vors [2], with 1 study documenting 80% of female
and 46% of male allogeneic HCT survivors reporting
sexual problems 5 years post-HCT [10]. Despite prev-
alence of sexual problems, only half of patients, in 1study, reported discussion of sexuality with their
health care provider [11]. Sexual problems can mani-
fest as lower rates of sexual activity, satisfaction,
response, and performance. Often caused by physio-
logic changes secondary to disease or treatment (eg,
ovarian failure, cGVHD-related vaginal stenosis or
mucosal changes, gonadal or cavernosal arterial insuf-
ficiency), sexual dysfunction also can involve a complex
interaction between physical, psychosocial, and rela-
tional issues. Several hormonal and mechanical inter-
ventions have been described for sexual difficulties,
although no treatments have been tested in females
in randomized trials. There is some evidence that brief
counseling, as well as education that focuses on cou-
ples communication and gradually increasing and
relearning pleasurable and intimate behaviors, are
helpful.
COGNITIVE DIFFICULTIES
Survivors frequently complain of cognitive diffi-
culties after HCT, and evidence of impairment on ob-
jective tests have been noted in 60% of adult HCT
survivors at least 2 years after transplant [12]. A range
of cognitive functions may be affected, including at-
tention, concentration learning, memory, processing
speed, executive function, and fine motor control.
Few specific risk factors of HCT have been identified;
however, both HCT and GVHD treatments may
play a role, along with health difficulties, fatigue,
and mood. There currently are no good instruments
to screen for cognitive difficulties, although one is
being developed (http://www.facit.org/qview/qlist.
aspx). Referral to a neuropsychologist for further eval-
uation and rehabilitation is recommended if significant
cognitive difficulties interfere with functioning. Treat-
ment may include compensatory strategy training,
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chostimulants, antidepressants, or anxiolytics), or
cognitive-behavioral psychotherapy.POSITIVE CHANGES
The majority of HCT survivors report experienc-
ing positive changes post-HCT [4], as well. These in-
clude greater inner strength and appreciation for life,
closer interpersonal relationships, reprioritizing ‘‘what
really matters,’’ renewed faith, and sense of gratitude.
The ability to find meaning in the experience may help
to buffer some of the adverse psychosocial affects of
HCT.THE IMPACTOF HCTON FAMILY
CAREGIVERS
Although family caregivers are critical to the re-
covery and well-being, and even survival [13], of
HCT survivors, little attention has been paid to the
impact of HCT on their physical and psychosocial
well-being. Spouse caregivers can experience higher
levels of anxiety and depression than survivors in the
peritransplant period, and distress levels similar to
that of survivors in the years to follow [14], as well as
fatigue, sexual difficulties, and sleep problems [14].
They also may suffer from a greater sense of isolation
and limited social support than survivors, and experi-
ence fewer positives [14]. Caregiver well-being should
be monitored, and they may need permission to seek
help and support for themselves, as well as help under-
standing that if they do not take care of themselves they
will not be able to provide the quality or length of care
for the survivor that they desire.ADDRESSING PSYCHOSOCIAL SEQUELAE:
WHY IS IT IMPORTANTANDWHAT CANWE
DO?
Psychosocial issues, such as elevated distress and
depression, can predict adherence [7], slower or poorer
return of function, and even survival rates [8]. Early
identification and referral for psychosocial problems
can result in better satisfaction with care, improved
patient-doctor communication, fewer complications,
and improved outcomes. The recent Institute of Med-
icine report, Cancer Care for the Whole Patient: Meeting
Psychosocial Health Needs, states high-quality care is not
possible without addressing patients’ psychosocial
health needs, which must become standard care. Pa-
tient education, support, assessment and treatment
are critical elements to addressing psychosocial con-
cerns of survivors and their caregivers.
To be most effective, patient assessment and edu-
cation should take place throughout the HCT process,from pretransplant evaluations, to determine patient
and family strengths and devise individualized, multi-
disciplinary treatment plans (eg, see Bryant et al [15]),
through continued surveillance of both medical and
psychosocial issues during survivorship. Development
of treatment summaries and survivorship care plans
that include psychosocial issues is a first step. Patient-
and caregiver-focused educational materials and sup-
port services are available through advocacy groups
such as BMT Info Net, nbmtLINK, and the NMDP.
Further development of survivorship-specific mate-
rials and resources for support and intervention is crit-
ical, as is standardization of delivery of psychosocial
care by educating heath care providers, empowering
patients and families, and providing access to a central
source of information for both.ACKNOWLEDGMENTS
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